On Friday, Summit Therapeutics Inc (NASDAQ: SMMT) opened lower -0.28% from the last session, before settling in for the closing price of $3.51. Price fluctuations for SMMT have ranged from $1.30 to $5.22 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -28.65% annually for the last half of the decade. Company’s average yearly earnings per share was noted 75.76% at the time writing. With a float of $82.98 million, this company’s outstanding shares have now reached $701.66 million.
In an organization with 105 employees, it is important to assess its efficiency.
Summit Therapeutics Inc (SMMT) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Summit Therapeutics Inc is 88.17%, while institutional ownership is 4.64%. The most recent insider transaction that took place on Mar 27 ’24, was worth 201,874. In this transaction Chief Executive Officer of this company bought 54,321 shares at a rate of $3.72, taking the stock ownership to the 24,923,800 shares. Before that another transaction happened on Mar 27 ’24, when Company’s Chief Executive Officer bought 26,000 for $3.72, making the entire transaction worth $96,720. This insider now owns 520,814 shares in total.
Summit Therapeutics Inc (SMMT) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.50 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 75.76% per share during the next fiscal year.
Summit Therapeutics Inc (NASDAQ: SMMT) Trading Performance Indicators
Check out the current performance indicators for Summit Therapeutics Inc (SMMT). In the past quarter, the stock posted a quick ratio of 9.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.54, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.29 in one year’s time.
Technical Analysis of Summit Therapeutics Inc (SMMT)
Let’s dig in a bit further. During the last 5-days, its volume was 1.3 million. That was inferior than the volume of 2.23 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 13.71%. Additionally, its Average True Range was 0.31.
During the past 100 days, Summit Therapeutics Inc’s (SMMT) raw stochastic average was set at 48.35%, which indicates a significant increase from 19.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.12% in the past 14 days, which was lower than the 106.33% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.15, while its 200-day Moving Average is $2.72. However, in the short run, Summit Therapeutics Inc’s stock first resistance to watch stands at $3.59. Second resistance stands at $3.67. The third major resistance level sits at $3.80. If the price goes on to break the first support level at $3.38, it is likely to go to the next support level at $3.25. Assuming the price breaks the second support level, the third support level stands at $3.17.
Summit Therapeutics Inc (NASDAQ: SMMT) Key Stats
There are currently 701,703K shares outstanding in the company with a market cap of 2.46 billion. Presently, the company’s annual sales total 0 K according to its annual income of -614,930 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -36,570 K.
